Overview >

Below is a summary of the current status of our three clinical trials.

Dermal Wound Healing – CVBT initiated its diabetic wound healing program in 2004 and completed pre-clinical efficacy and toxicity studies with human fibroblast growth factor (FGF-1). An FDA-authorized Phase I study in diabetic patients was completed in 2008 in which topically-applied FGF-1 to diabetic wounds was well tolerated and showed no adverse effects.

To accelerate CVBT's wound healing program, the company has in-licensed Phase I and Phase II clinical trial data for its FGF-1 diabetic wound healing compound. This data coupled with CVBT's own internal data indicates FGF-1 is safe and efficacious for diabetes patients suffering from dermal wounds, and will be used to apply for approval to advance to a pivotal Phase III trial and Fast Track designation.

Severe Coronary Heart Disease (CHD) – A U.S. FDA approved Phase II trial for heart patients with severe coronary heart disease has begun in an expanded patient population in the United States and internationally. The following sites are now open for patient enrollment.

If you are interested in learning more about enrolling in this trial please complete our Clinical Trial Inquiry Form.

Peripheral Artery Disease –The US FDA has authorized a Phase I clinical trial for Peripheral Artery Disease (PAD) specifically for patients with intermittent claudication (cramping pain and weakness in the legs during walking).

Note: While the FDA ultimately determines the course and timing of clinical trials, this timeline represents an estimate as to when certain research milestones could be achieved in the development of those applications. The information is subject to change at any time and is likely to change. Actual results may differ materially. It is provided for information purposes only. Investment decisions should not be made based on the timeline. CVBT does not undertake to update the timeline on this web site. This information is only an estimate.

Use of this site constitutes agreement to our Terms and Conditions
and Privacy Policy. Site Design and Contents © 2011 CardioVascular BioTherapeutics, Inc. All Rights Reserved.

Some content on this site requires the free Adobe Reader.